Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Imbria Pharmaceuticals, Inc.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Hypertrophic Cardiomyopathy consistent with current US and European guidelines
Ability to perform an upright treadmill cardiopulmonary exercise test
Agreement to abide by contraceptive requirements
You may not be if
Clinically significant concurrent condition which could prevent the patient from performing any of the protocol-specified assessments, represent a safety concern if the patient participates in the trial or could confound trial assessments of safety or tolerability
Women who are pregnant, planning to become pregnant or lactating
Participation in another clinical study involving a test product or invasive medical device within 28 days (or within 5 elimination half-lives of the respective test product, whichever is longer), prior to first dosing
Clareo Health | A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
